Expression of the Sodium/Iodide Symporter in Human Prostate Adenocarcinoma - 20/08/11
Reprint requests: Diego Russo, M.D., Department of Pharmacobiological Sciences, University of Catanzaro “Magna Graecia,” Viale Europa, Germaneto, 88100 Catanzaro, ItalyRésumé |
Objective |
To analyze expression of the sodium/iodide symporter (NIS) in tissue specimen from a large series of patients with prostate adenocarcinoma. Few data are available on the NIS expression in prostate tumor tissues.
Methods |
NIS protein expression was examined by immunohistochemistry in 78 tumor tissue specimen and their non-neoplastic counterparts. Total ribonucleic acid was extracted for semiquantitative reverse transcription polymerase chain reaction analysis of NIS transcript. The relationship between NIS expression and Gleason score, prostate-specific antigen levels and stage was also investigated.
Results |
NIS protein was expressed in 41 of 78 prostate cancer (52.4%) and was located predominantly intracellularly, whereas immunoreactivity was missing in nontumor hyperplastic prostatic tissue. Absence of expression was mainly because of reduced or lost gene transcription, as detected by reverse transcription polymerase chain reaction. A statistically significant relationship was detected between presence of NIS expression and some markers of aggressiveness including stage ≥pT2a (P = .007) and Gleason score ≥8 (P = .014).
Conclusions |
Our data demonstrate the presence of NIS transcript and protein in about half of prostate cancer tissues and its relationship with clinical markers of aggressiveness. Thus, it may potentially serve as a biomarker for defining individuals with biologically active prostate cancer.
Le texte complet de cet article est disponible en PDF.Plan
| This study was supported by grants from the “Fondazione Umberto Di Mario” (to D.R. and S.F.). |
|
| S. M. Lepore is fellow of Ph.D. Program in Pharmaceutical Sciences at University of Catanzaro. |
|
| Michele Navarra and Salvatore Micali contributed equally to this work. |
Vol 75 - N° 4
P. 773-778 - avril 2010 Retour au numéro
Article précédent
- Osteoblast-specific Factor 2 Expression in Prostate Cancer-associated Stroma: Identification Through Microarray Technology
- Bungo Furusato, Toshiyuki Tsunoda, Syed Shaheduzzaman, Martin E. Nau, Maryanne Vahey, Gyorgy Petrovics, David G. McLeod, Seiji Naito, Senji Shirasawa, Shiv Srivastava, Isabell A. Sesterhenn
- Polymorphisms in hOGG1 and XRCC1 and Risk of Prostate Cancer: Effects Modified by Plasma Antioxidants
- Jianjun Zhang, Ishwori B. Dhakal, Graham Greene, Nicholas P. Lang, Fred F. Kadlubar
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?